Navigation Links
Genetic predictor of breast cancer response to chemotherapy
Date:5/11/2012

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy.

The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of most benefit to patients whose cancer is driven by HER2 and antiestrogens benefit patients whose breast cancer is hormonally driven. Gene signatures are increasingly available for different cancer types and can be used to predict patient prognosis.

Researchers from McMaster University, in association with the Juravinski Hospital and Cancer Center, analyzed the expression of the enzyme TOP2A (DNA topoisomerase) and β-tubulin, which are the targets of commonly used chemotherapy drugs (anthracycline and taxane) in hundreds of breast tumors. Combining the results from the tumor samples analyses allowed the researchers to build gene expression 'signatures' that measure the susceptibility of tumor cells to chemotherapy.

Both of the 'signatures' were separately able to predict which patients achieved a complete response (where invasive or metastatic cancer could no longer be detected) and together the two indices together were even more accurate at predicting response to chemotherapy.

Prof John Hassell, who led this study, commented, " Our results clearly demonstrate the practicality of using gene expression to personalize chemotherapy treatment for breast cancer patients. Identifying patients who will not benefit from a specific treatment means that they can be moved to a different treatment plan, and the earlier appropriate treatment is started the more likely it is that the patients will benefit from it."


'/>"/>
Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-020-319-22370
BioMed Central
Source:Eurekalert

Page: 1

Related medicine news :

1. Advanced genetic screening method may speed vaccine development
2. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
3. Some women may be genetically predisposed to smoking-related hot flashes
4. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Research Gets Closer to Genetic Roots of Glaucoma
7. Genetic variants, tobacco exposure and lung cancer risk
8. Study of half siblings provides genetic clues to autism
9. Certain Genetic Regions May Be Tied to Osteoporosis
10. Head, Body Lice Are Genetically Very Similar
11. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Virginia Beach resident Sean Kelly ... turned towards the water to find peace and set out to accomplish a personal ... and turned to the internet. He came across the story of another special operations ...
(Date:6/23/2016)... ... 2016 , ... The annual Blue Ribbon Highlights Session took ... and Movement Disorders. This special session provides a critical review of the best ... of both clinical and basic research presented by delegates. , Of the ...
(Date:6/23/2016)... ... 2016 , ... The U.S. Supreme Court decision on immigration has significant consequences ... Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would have ... worked in this country illegally, even though the newly - issued green cards are ...
(Date:6/23/2016)... ... 23, 2016 , ... For the second time this year, ... Medical Education program, this time in pediatrics. The news from the Accreditation Council ... training that will begin in July 2017. ACGME had previously accredited Memorial’s Physical ...
(Date:6/23/2016)... Research Triangle Park, NC (PRWEB) , ... June 23, 2016 , ... ... Alzheimer’s disease, is announcing that the U.S. Food and Drug Administration (FDA) has granted ... T3D-959 in a limited number of subjects who completed the main Phase 2a study ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... June 23, 2016  The National Pharmaceutical Council ... the health policy research organization as its newest ... MD, senior vice president and chief scientific officer, ... on the NPC Board of Directors. ... Mallinckrodt has joined us in support of our ...
Breaking Medicine Technology: